相似文献
1
Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998.
Emerg Infect Dis. 2001 Jan-Feb;7(1):113-22. doi: 10.3201/eid0701.010116.
2
Molecular Characterization of Stenotrophomonas maltophilia isolates from cystic fibrosis patients and the hospital environment.
Infect Control Hosp Epidemiol. 2009 Aug;30(8):753-8. doi: 10.1086/598683.
3
Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.
Pediatr Pulmonol. 2003 Feb;35(2):99-107. doi: 10.1002/ppul.10216.
4
Characterization of small-colony-variant Stenotrophomonas maltophilia isolated from the sputum specimens of five patients with cystic fibrosis.
J Clin Microbiol. 2007 Feb;45(2):529-35. doi: 10.1128/JCM.01444-06. Epub 2006 Nov 29.
5
Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence.
BMC Microbiol. 2011 Jul 5;11:159. doi: 10.1186/1471-2180-11-159.
6
Genomic information on Stenotrophomonas maltophilia ST264 isolated from a cystic fibrosis pediatric patient in Brazil.
Braz J Microbiol. 2020 Sep;51(3):1125-1127. doi: 10.1007/s42770-019-00214-y. Epub 2019 Dec 19.
7
Molecular epidemiology of Stenotrophomonas maltophilia in a university hospital.
J Hosp Infect. 2002 Oct;52(2):88-92. doi: 10.1053/jhin.2002.1280.
8
Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis.
J Hosp Infect. 2003 Nov;55(3):180-3. doi: 10.1016/s0195-6701(03)00299-8.
9
Stenotrophomonas maltophilia strains from cystic fibrosis patients: genomic variability and molecular characterization of some virulence determinants.
Int J Med Microbiol. 2011 Jan;301(1):34-43. doi: 10.1016/j.ijmm.2010.07.003. Epub 2010 Oct 16.
10
Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
Jpn J Infect Dis. 2007 May;60(2-3):82-6.
引用本文的文献
1
Resistance evolution can disrupt antibiotic exposure protection through competitive exclusion of the protective species.
ISME J. 2022 Oct;16(10):2433-2447. doi: 10.1038/s41396-022-01285-w. Epub 2022 Jul 20.
2
Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients.
PeerJ. 2015 Sep 15;3:e1223. doi: 10.7717/peerj.1223. eCollection 2015.
3
Identification, molecular characterisation and antimicrobial susceptibility of genomovars of the Burkholderia cepacia complex in Spain.
Eur J Clin Microbiol Infect Dis. 2012 Dec;31(12):3385-96. doi: 10.1007/s10096-012-1707-6. Epub 2012 Aug 2.
4
Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.
Clin Microbiol Rev. 2012 Jan;25(1):2-41. doi: 10.1128/CMR.00019-11.
5
The binding of triclosan to SmeT, the repressor of the multidrug efflux pump SmeDEF, induces antibiotic resistance in Stenotrophomonas maltophilia.
PLoS Pathog. 2011 Jun;7(6):e1002103. doi: 10.1371/journal.ppat.1002103. Epub 2011 Jun 30.
6
Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence.
BMC Microbiol. 2011 Jul 5;11:159. doi: 10.1186/1471-2180-11-159.
7
Clinical significance of microbial infection and adaptation in cystic fibrosis.
Clin Microbiol Rev. 2011 Jan;24(1):29-70. doi: 10.1128/CMR.00036-10.
8
The changing microbial epidemiology in cystic fibrosis.
Clin Microbiol Rev. 2010 Apr;23(2):299-323. doi: 10.1128/CMR.00068-09.
9
Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
BMC Microbiol. 2010 Apr 7;10:102. doi: 10.1186/1471-2180-10-102.
10
Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations.
Appl Environ Microbiol. 2010 Mar;76(6):1746-58. doi: 10.1128/AEM.02817-09. Epub 2010 Jan 22.
本文引用的文献
1
High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.
Science. 2000 May 19;288(5469):1251-4. doi: 10.1126/science.288.5469.1251.
2
Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia.
J Clin Microbiol. 1999 Nov;37(11):3594-600. doi: 10.1128/JCM.37.11.3594-3600.1999.
3
Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing.
Infect Control Hosp Epidemiol. 1999 Aug;20(8):553-6. doi: 10.1086/501668.
4
Faucet aerators: A source of patient colonization with Stenotrophomonas maltophilia.
Am J Infect Control. 1999 Feb;27(1):59-63. doi: 10.1016/s0196-6553(99)70077-5.
5
Microbiology of sputum from patients at cystic fibrosis centers in the United States.
Clin Infect Dis. 1998 Jul;27(1):158-63. doi: 10.1086/514631.
6
Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples.
J Clin Microbiol. 1998 Jul;36(7):1953-8. doi: 10.1128/JCM.36.7.1953-1958.1998.
7
Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence.
Pediatr Pulmonol. 1998 May;25(5):304-8. doi: 10.1002/(sici)1099-0496(199805)25:5<304::aid-ppul3>3.0.co;2-i.
8
Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.
Clin Microbiol Rev. 1998 Jan;11(1):57-80. doi: 10.1128/CMR.11.1.57.
9
Epidemiological typing of Stenotrophomonas maltophilia.
J Hosp Infect. 1997 Aug;36(4):261-6. doi: 10.1016/s0195-6701(97)90052-9.
10
Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens.
Infect Control Hosp Epidemiol. 1997 May;18(5):316-21. doi: 10.1086/647618.
Zotero 插件